Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Yarrow Bioscience, Inc. (YARW)
Price$30.21Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 | $21.0M | $443,000 | $3.6M | $4.6M | $674,000 | — |
| Gross profit | — | — | — | — | −$2.4M | $19.6M | $443,000 | $3.6M | — | — | — |
| Gross margin | — | — | — | — | −259.61% | 93.37% | 100.00% | 100.00% | — | — | — |
| Research & development | $19.2M | $30.9M | $16.3M | $18.4M | $19.5M | $43.5M | $51.2M | $64.5M | $29.0M | $11.3M | $2.9M |
| Operating expenses | $30.3M | $44.1M | $29.7M | $34.8M | $39.8M | $272.1M | $96.3M | $78.5M | $34.2M | $15.0M | $4.6M |
| Operating income | −$29.7M | −$43.6M | −$29.3M | −$34.3M | −$38.9M | −$252.5M | −$95.9M | −$74.9M | −$29.6M | −$14.3M | −$4.6M |
| Operating margin | −5,219.12% | −8,709.98% | −6,900.47% | −7,189.73% | −4,179.48% | −1,203.00% | −21,641.76% | −2,083.23% | −645.85% | −2,126.41% | — |
| EBITDA | −$29.7M | −$43.6M | −$29.3M | −$34.2M | −$38.8M | −$252.2M | −$95.5M | −$74.6M | — | — | — |
| EBITDA margin | −5,215.09% | −8,709.18% | −6,900.47% | −7,174.63% | −4,167.78% | −1,201.38% | −21,562.75% | −2,074.35% | — | — | — |
| Net income | −$26.5M | −$39.8M | −$28.5M | −$23.2M | −$73.3M | −$255.6M | −$95.2M | −$74.2M | −$29.1M | −$14.1M | −$4.6M |
| Net profit margin | −4,646.14% | −7,950.90% | −6,710.38% | −4,865.83% | −7,876.37% | −1,217.40% | −21,484.88% | −2,062.95% | −634.57% | −2,087.24% | — |
| Basic EPSper basic share | -$31.00 | -$46.50 | -$139.00 | -$364.00 | -$1,282.00 | $7,099.10 | $10,108.11 | $10,333.33 | -$82,018.02 | -$40,648.65 | -$13,981.98 |
| Diluted EPSper diluted share | -$31.00 | -$46.50 | -$139.00 | -$364.00 | -$1,282.00 | $7,099.10 | $10,108.11 | $10,333.33 | -$82,018.02 | -$40,648.65 | -$13,981.98 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Domzalski David | 438.78K |
Harsch Mutya | 121.9K |
Stuart Iain | 112.36K |
Zeronda Tyler | 99.79K |
LEPORE PATRICK G | 51.47K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 15, 2025Form 4 | LEPORE PATRICK GDirector | BuyCommon Stock | 15.0K | $2.92 | $43.8K | 51.5K |